.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ state-of-the-art bosom cancer cells as well as energetic or even steady brain metastases revealed steady intracranial activity and also systemic efficacy of T-DXd.